Bipolar Disorder Treatment Market to Expand USD 15.67 Billion by 2034 Amid Rising Awareness and Urbanization

The bipolar disorder treatment market is projected to be valued at USD 9.74 billion in 2025 reaching around USD 15.67 billion by 2034, at CAGR of 5.43% over the forecast period.

Ottawa, Sept. 22, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global bipolar disorder treatment market size was estimated at USD 9.24 billion in 2024 and is anticipated to rise to about USD 15.67 billion by 2034, growing at a CAGR of 5.43% during the forecast period.

Changing lifestyle and faster urbanization are leading to the development of bipolar disorders, and the accelerating awareness regarding their treatment is fueling the market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5473

Key Takeaways

North America held a major share of the market in 2024.
Asia-Pacific is expected to be the fastest-growing region during 2025-2034.
By drug class, the antipsychotics segment led the bipolar disorder treatment market in 2024.
By drug class, the antidepressants segment is expected to witness the fastest growth in the studied years.
By distribution channel, the hospital pharmacies segment was dominant in the market in 2024.
By distribution channel, the online pharmacies segment is expected to grow rapidly during 2025-2034.

What is the Bipolar Disorder Treatment?

The global bipolar disorder treatment market encompasses combinations of mood-stabilizing drugs, psychotherapy (like CBT), and lifestyle adjustments like consistent sleep and exercise. Currently, the research area is fostering the exploration of precision psychiatry for customized treatments, employing digital health tools, and researching ketamine and melatonin-based therapies for specific symptoms and underlying mechanisms, such as circadian rhythm disruption. These treatments are widely used in the management of manic or mixed episodes, highlighting maintenance therapy with long-acting injectables and mood stabilizers, including lithium and anticonvulsants.

What are the Growth Drivers in the Bipolar Disorder Treatment Market?

The worldwide rise in bipolar disorder prevalence and the expansion of public awareness and societal stepping into acceptance of mental health concerns to lower stigma, support more people to seek and adhere to treatment. As well as the widespread pharmaceutical industries are putting efforts into R&D by significant investment for the development of new therapies and the growth of their product portfolios. Other approaches, particularly AI-enabled tools, wearable medical devices, and other digital technologies, are assisting in early and more precise detection of mood states and mental concerns.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Key Drifts in the Bipolar Disorder Treatment Market?

Across the market, expanding collaborations with leading players for innovations in the diverse neurological conditions, including depression, mood disorders, etc.

In August 2025, CURE GABA-A partnered with Grann Pharmaceuticals to advance rare neurological therapies.
In May 2025, Thermo Fisher Scientific collaborated with Cybin Inc. to promote the Phase 3 clinical supply and potential commercial manufacturing of CYB003, a robust treatment for Major Depressive Disorder.
In July 2024, San Diego biotechnology company Autobahn Therapeutics raised $100 million to advance an experimental mood disorder medicine into mid-stage testing.

What is the Evolving Challenge in the Market?

A major barrier in the bipolar disorder treatment market is a delayed diagnosis due to bipolar disorder symptoms, which can further start mimicking unipolar depression. Along with this, a lack of concurrence on the highly efficient treatment plans for psychotic bipolar disorder raises the requirement for greater research.

Regional Analysis

Why did North America Dominate the Market in 2024?

In 2024, North America held the dominating share of the bipolar disorder treatment market. This region’s strong healthcare systems, comprising well-developed healthcare infrastructure and novel therapies, act as a significant catalyst. Alongside government initiatives, particularly the Affordable Care Act in the U.S., supporting the growth of access to mental health care, and government encouragement for mental health services, are propelling the overall regional progress. Latest initiatives, such as the ENIGMA-BD consortium, are promoting global alliances to demonstrate large-scale brain imaging studies, focusing on better understanding the underlying brain structures and functions in bipolar disorder.

Why did the Asia Pacific Grow Significantly in the Market in 2024?

During 2025-2034, the Asia Pacific is anticipated to expand rapidly in the bipolar disorder treatment market. Asia Pacific countries are facing the expansion of urbanization and lifestyle changes, which are further boosting the various developments in the robust pharmaceutical companies' hub.

Additionally, ASAP is widely involved in the development of medication options, such as second-generation antipsychotics (SGAs) and novel mood stabilizers (MSs), likewise cariprazine. Whereas the emergence of Repetitive Transcranial Magnetic Stimulation (rTMS) is leveraging possible advantages for treatment-resistant bipolar depression. Furthermore, the Korean guideline supports combination therapies (mood stabilizer + atypical antipsychotic) for psychotic mania, mixed mania, and psychotic depression.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By drug class analysis

Which Drug Class Led the Bipolar Disorder Treatment Market in 2024?

The antipsychotics segment captured the biggest revenue share of the market in 2024. Ongoing developments in this drug class, mainly long-acting injectables, are facilitating enhanced beneficial effects for patients. However, the broader use of selective serotonin reuptake inhibitors (SSRIs) for better outcomes has been raising their prescription rates. Inclusion of other therapeutic solutions comprises sublingual films, in which one contains the active ingredient of dexmedetomidine (originally approved for acute agitation in schizophrenia), providing new routes for faster-acting, at-home treatments for acute agitation in bipolar disorder.

On the other hand, the antidepressants segment is predicted to expand at a rapid CAGR in the coming era. A recent study says that these kinds of drugs have a potential effect in Bipolar II cases with a short-term action. The bupropion is linked with the reduced risk of triggering a manic switch. Alongside, mainly FDA-approved drugs, including quetiapine, lurasidone, cariprazine, olanzapine-fluoxetine combination, and lumateperone, are used in the treatment of acute depressive episodes in bipolar I disorder.

By distribution channel

Why did the Hospital Pharmacies Segment Dominate the Market in 2024?

The hospital pharmacies segment registered dominance in the bipolar disorder treatment market in 2024. The contribution of leading companies in the bipolar disorder treatment is concentrating on the expansion of their portfolios through novel drug approvals and accelerated applications for existing therapeutics, which directly influences the types of treatments hospital pharmacies dispense. Whereas a clinical pharmacist supports the improvements in the outcomes for bipolar disorder patients after hospital discharge, like better quality of life and lowered depressive symptoms.

The online pharmacies segment is estimated to register the fastest growth during 2025-2034. These pharmacies are offering distinct and convenient access to drugs, particularly for patients with mobility concerns or who live in remote areas. Developing digital health tools for monitoring and adherence, as well as transforming AI and pharmacogenomics, are assisting in tailored treatment. Moreover, evolving economies and other regions are highly looking for affordable solutions, especially generics and online access to therapeutics, which makes online pharmacies a crucial aspect of the distribution channel.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Developments in the Bipolar Disorder Treatment Market

In September 2025, NeuroKaire, a biotech company, introduced BrightKaire, a test that relies on a “brain in a dish” technology that assists clinicians in choosing the best antidepressant medication for patients with MDD.
In May 2025, Sunshine Biopharma Inc., a pharmaceutical company, unveiled a new generic prescription drug, Lurasidone, for treating schizophrenia and bipolar depression.
In March 2025, Vanda Pharmaceuticals Inc. made a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti (milsaperidone) for the treatment of acute bipolar I disorder and schizophrenia.
In March 2025, Baszucki Group unveiled two new initiatives across multiple sites, demonstrating the efficiency of ketogenic therapy for children and adolescents with bipolar disorder.

Bipolar Disorder Treatment Market Key Players List

Amneal Pharmaceuticals Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bristol Myers Squibb Co.
Eli Lilly and Co.
Gedeon Richter Plc
GlaxoSmithKline Plc
H Lundbeck AS
Intra-Cellular Therapies Inc.
Mallinckrodt Plc
Novartis AG
Otsuka Holdings Co. Ltd.
Pfizer Inc.
Sumitomo Pharma Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
The London Psychiatry Centre
Wockhardt Ltd.
Zydus Lifesciences Ltd.

Browse More Insights of Towards Healthcare:

The global topical drug delivery market is valued at US$ 247.3 billion in 2024, expected to increase to US$ 268.99 billion in 2025, and projected to nearly double, reaching US$ 568.65 billion by 2034. This reflects a steady expansion at a CAGR of 8.76% between 2025 and 2034.

The global nerve conduits, wraps, protectors, caps, and connectors market was worth US$ 255 million in 2023 and is forecasted to grow significantly, reaching US$ 691.98 million by 2034, advancing at a CAGR of 9.5% during 2024–2034.

The musculoskeletal disorders treatment market is set to expand from US$ 209.01 billion in 2025 to US$ 353.12 billion by 2034, progressing at a 6% CAGR throughout the forecast period.

The anxiety disorders treatment market is anticipated to rise from US$ 12.33 billion in 2025 to US$ 16.95 billion by 2034, growing at a modest CAGR of 3.6% between 2025 and 2034.

The global atrial fibrillation treatment market stands at US$ 24.26 billion in 2024 and is projected to climb to US$ 40.27 billion by 2034, witnessing a CAGR of 5.2% during the period.

The regulatory affairs market is valued at US$ 16 billion in 2024, expected to reach US$ 17.37 billion in 2025, and further expand to US$ 36.33 billion by 2034, advancing at a CAGR of 8.55% from 2025 to 2034.

The health coach market is worth US$ 17.5 billion in 2024, projected to grow to US$ 18.66 billion in 2025, and expected to reach US$ 33.26 billion by 2034, progressing at a CAGR of 6.64% over the forecast timeline.

The U.S. healthcare staffing market is estimated at US$ 19.5 billion in 2024, with growth to US$ 20.62 billion in 2025, and an expected value of US$ 34.09 billion by 2034. The market is anticipated to expand at a CAGR of 5.74% between 2025 and 2034.

Globally, the supplemental health market is on a strong growth path, expected to generate substantial revenues over 2025–2034. The U.S. supplemental health market was valued at US$ 38.62 billion in 2024, is projected to grow to US$ 40.77 billion in 2025, and is forecasted to reach US$ 65.19 billion by 2034, registering a CAGR of 5.64% across the forecast period.

Segments Covered in the Report

By Drug Class

Mood stabilizer
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5473

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.